Clinical Efficacy Evaluation of Sirolimus in Congenital Hyperinsulinism
Background. Congenital hyperinsulinism (CHI) is a rare and life-threatening genetic disorder. Sirolimus as a mammalian target of rapamycin inhibitor may be helpful in patients with CHI who do not respond well to other treatments including diazoxide and octreotide. However, the safety and efficacy of...
Saved in:
Main Authors: | Somayyeh Hashemian, Reza Jafarzadeh Esfehani, Siroos Karimdadi, Rahim Vakili, Daniel Zamanfar, Amirhossein Sahebkar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2020/7250406 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case Report: The importance of genetic counseling for families with hyperinsulinism
by: Victoria R. Sanders, et al.
Published: (2025-01-01) -
First Report of Diabetes Phenotype due to a Loss-of-Function ABCC8 Mutation Previously Known to Cause Congenital Hyperinsulinism
by: Theocharis Koufakis, et al.
Published: (2019-01-01) -
Dramatic Response to Sirolimus in Lymphangioleiomyomatosis
by: Dmitry Rozenberg, et al.
Published: (2013-01-01) -
Arterial Calcium Stimulation with Hepatic Venous Sampling in the Localization Diagnosis of Endogenous Hyperinsulinism
by: Paloma Moreno-Moreno, et al.
Published: (2016-01-01) -
A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation
by: Bertram L. Kasiske, et al.
Published: (2012-01-01)